<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582840</url>
  </required_header>
  <id_info>
    <org_study_id>D1695C00001sub</org_study_id>
    <nct_id>NCT02582840</nct_id>
  </id_info>
  <brief_title>The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM</brief_title>
  <official_title>A Clinical Pharmacology and Long Term Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Who Have Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, single-blind, 3 arm, parallel group, placebo controlled PK/PD study will
      enrol 30 Japanese male and female patients with T1DM and age 18 to 65 years, with inadequate
      glycemic control on insulin defined as HbA1c ≥ 7.0% and ≤ 10.0% at screening visit.
      lacebo-controlled design. Patients will be randomized in a 1:1:1 ratio into one of the 3
      single-blinded treatment arms; dapagliflozin 5 mg, dapagliflozin 10 mg or placebo. CSII user
      are excluded.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dapagliflozin Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dapagliflozin Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dapagliflozin Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dapagliflozin Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dapagliflozin 3-O-Glucuronide Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dapagliflozin 3-O-Glucuronide Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dapagliflozin 3-O-Glucuronide Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dapagliflozin 3-O-Glucuronide Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dapagliflozin Ratio of Metabolite to Parent AUC of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7 - Pharmacodynamic (PD) Set</measure>
    <time_frame>Baseline (the last available assessment prior to the first dose of study medication), Day 7</time_frame>
    <description>The 24-hour period is defined based on the morning void, from the first morning void to the one of the next day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Daily Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</measure>
    <time_frame>Baseline (the last available assessment on or prior to the first dose of study medication), Day 7</time_frame>
    <description>Total daily insulin dose is defined as the sum of all insulin doses (basal+bolus+premixed) for each day. Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Basal Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</measure>
    <time_frame>Baseline (the last available assessment on or prior to the first dose of study medication), Day 7</time_frame>
    <description>Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Bolus Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</measure>
    <time_frame>Baseline (the last available assessment on or prior to the first dose of study medication), Day 7</time_frame>
    <description>Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG) (mg/dL) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</measure>
    <time_frame>Baseline (the last available assessment on or prior to the first dose of study medication), Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated Systolic Blood Pressure (mmHG) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</measure>
    <time_frame>Baseline (the last available assessment on or prior to the first dose of study medication), Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>dapagliflozin 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dapagliflozin tablet 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dapagliflozin 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dapagliflozin tablet 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dapagliflozin tablet 5mg placebo or 10 mg placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 5mg</intervention_name>
    <description>Dapagliflozin, a blood glucose lowering drug. Oral dose</description>
    <arm_group_label>dapagliflozin 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>Dapagliflozin, a blood glucose lowering drug. Oral dose</description>
    <arm_group_label>dapagliflozin 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Placebo tablet. Oral dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Written Informed Consent Subjects or their legally responsible representatives
             must be willing and able to give signed and dated written informed consent.

          -  Target Population Diagnosis of T1DM. In addition, the following criteria also needs to
             be met; Central laboratory test of C-peptide &lt; 0.7 ng/mL Subject re-enrolment: This
             study does not permit the re-enrolment of a subject who has discontinued the study as
             a screen failure

          -  Insulin use for at least 12 months prior to the enrolment per subject report or
             medical records and Method of insulin administration (MDI) must have been unchanged
             for at least 3 months prior to the enrolment per subject report or medical records.
             Subjects must be taking a total daily insulin dose of ≥ 0.3 U/kg/day for at least 3
             months prior to the enrolment. CSII users are excluded. MDI insulin administration
             subject must be on ≥ 3x injections per day.

          -  Gender and reproductive Status Japanese men and women.

          -  HbA1c eligibility criteria include: Screening Visit: Central laboratory HbA1c ≥ 7.0 %
             and ≤ 10.0 % (One repeat HbA1c test for subjects in screening if their initial test
             result was an HbA1c ± 0.2% of the cut off values)

          -  BMI ≥ 20.0 kg/m², ≤ 35.0 kg/m² at visit 1

          -  Ages 18 to 65 years, inclusive - ≥ 18 years old and &lt; 20 years old must have assent
             forms signed and dated by their parents or guardians

        Exclusion Criteria:

          -  Target Disease Exceptions History of T2DM In cases where the subject has a history of
             T2DM and has a documented history of being auto-antibody positive for GAD65, tyrosine
             phosphatase IA-2/IA-2β, or Zinc Transporter 8 (ZnT8), or fasting c-peptide value below
             the lower limit of detection performed by local or central laborator, the subject will
             be eligible for screening

          -  Maturity onset diabetes of young (MODY), Pancreatic surgery, chronic pancreatitis, or
             other pancreatic disorders that could result in decreased β-cell capacity (eg,
             pancreatogenous diabetes)

          -  Any antihyperglycemic agent use, other than thiazolidinediones, or insulin, within 1
             month prior to the screening visit. Use of thiazolidinediones within 6 months prior to
             the screening visit.

          -  History of DKA requiring medical intervention (eg, emergency room visit and/or
             hospitalization) within 1 month prior to the enrolment

          -  History of hospital admission for glycemic control (either hyperglycemia or
             hypoglycemia) within 1 month prior to the enrolment

          -  Malignancy within 5 years of the enrolment (with the exception of treated basal cell
             or treated squamous cell carcinoma)

          -  History of bladder cancer

          -  History of radiation therapy to the lower abdomen or pelvis at any time Unstable
             pre-proliferative and proliferative retinopathy (untreated or under treatment).

          -  Physical and Laboratory Test Findings Aspartate aminotransferase (AST) &gt; 3x upper
             limit of normal (ULN) Alanine aminotransferase (ALT) &gt; 3x ULN Serum total bilirubin
             (TB) &gt; 2.0 mg/dL (34.2 μmol/L).

          -  Estimated GFR (eGFR) by the Japanese Society of Nephrology formula ≤ 60 mL/min/1.73m2.
             Hemoglobin ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for women.

          -  Positive for hepatitis B surface antigen or anti-hepatitis C virus antibody

          -  Abnormal Free T4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <results_first_submitted>October 3, 2017</results_first_submitted>
  <results_first_submitted_qc>August 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2019</results_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese patients with type 1 diabetes with inadequate glycemic control on insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>26 October 2015 to 04 June 2016, Japan, patients with type 1 diabetes mellitus.</recruitment_details>
      <pre_assignment_details>Of 62 patients who signed informed consent, 42 eligible patients randomized and completed the 7-day treatment period (Part A) of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo + Insulin</title>
          <description>Placebo administered orally once daily in the morning.</description>
        </group>
        <group group_id="P2">
          <title>Dapagliflozin 5mg + Insulin</title>
          <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
        </group>
        <group group_id="P3">
          <title>Dapagliflozin 10 mg + Insulin</title>
          <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo + Insulin</title>
          <description>Placebo administered orally once daily in the morning.</description>
        </group>
        <group group_id="B2">
          <title>Dapagliflozin 5mg + Insulin</title>
          <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
        </group>
        <group group_id="B3">
          <title>Dapagliflozin 10 mg + Insulin</title>
          <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.6" spread="10.62"/>
                    <measurement group_id="B2" value="37.0" spread="10.05"/>
                    <measurement group_id="B3" value="37.1" spread="10.21"/>
                    <measurement group_id="B4" value="38.9" spread="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=45 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Type 1 Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.89" spread="10.530"/>
                    <measurement group_id="B2" value="15.94" spread="9.235"/>
                    <measurement group_id="B3" value="14.69" spread="12.368"/>
                    <measurement group_id="B4" value="15.84" spread="10.561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (HbA1c)%</title>
          <units>percent of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.13" spread="0.835"/>
                    <measurement group_id="B2" value="7.91" spread="0.610"/>
                    <measurement group_id="B3" value="7.89" spread="0.553"/>
                    <measurement group_id="B4" value="7.98" spread="0.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134.00" spread="63.898"/>
                    <measurement group_id="B2" value="142.93" spread="49.930"/>
                    <measurement group_id="B3" value="133.36" spread="42.239"/>
                    <measurement group_id="B4" value="136.76" spread="51.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-Peptide</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 0.1 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" spread="0.083"/>
                    <measurement group_id="B2" value="13" spread="0.107"/>
                    <measurement group_id="B3" value="11" spread="0.036"/>
                    <measurement group_id="B4" value="0.12" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 0.1 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dapagliflozin Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
        <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
        <time_frame>Day 1-7</time_frame>
        <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Dapagliflozin Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
          <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
          <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.31" spread="26.42"/>
                    <measurement group_id="O2" value="162.09" spread="26.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dapagliflozin Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
        <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
        <time_frame>Day 1-7</time_frame>
        <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Dapagliflozin Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
          <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
          <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" spread="80.14"/>
                    <measurement group_id="O2" value="5.71" spread="52.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dapagliflozin Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
        <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
        <time_frame>Day 1-7</time_frame>
        <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Dapagliflozin Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
          <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
          <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="52.36" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dapagliflozin Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
        <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
        <time_frame>Day 1-7</time_frame>
        <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Dapagliflozin Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
          <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
          <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.72" spread="44.69" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="670.01" spread="36.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dapagliflozin 3-O-Glucuronide Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
        <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
        <time_frame>Day 1-7</time_frame>
        <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Dapagliflozin 3-O-Glucuronide Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
          <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
          <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.88" spread="31.95"/>
                    <measurement group_id="O2" value="136.62" spread="31.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dapagliflozin 3-O-Glucuronide Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
        <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
        <time_frame>Day 1-7</time_frame>
        <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Dapagliflozin 3-O-Glucuronide Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
          <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
          <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="56.43"/>
                    <measurement group_id="O2" value="6.25" spread="35.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dapagliflozin 3-O-Glucuronide Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
        <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
        <time_frame>Day 1-7</time_frame>
        <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Dapagliflozin 3-O-Glucuronide Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
          <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
          <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="52.36" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dapagliflozin 3-O-Glucuronide Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
        <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
        <time_frame>Day 1-7</time_frame>
        <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Dapagliflozin 3-O-Glucuronide Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
          <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
          <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345.87" spread="29.32" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="675.50" spread="23.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dapagliflozin Ratio of Metabolite to Parent AUC of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
        <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
        <time_frame>Day 1-7</time_frame>
        <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5mg + Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Dapagliflozin Ratio of Metabolite to Parent AUC of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set</title>
          <description>Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).</description>
          <population>Pharmacokinetic set – Part A (PK-A): The PK set consisted of all randomized subjects who had at least one dose of randomized study medication for Part A and had an evaluable plasma concentration data of dapagliflozin and/or its major metabolite dapagliflozin 3-O-glucuronide.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="44.26" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="0.70" spread="30.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7 - Pharmacodynamic (PD) Set</title>
        <description>The 24-hour period is defined based on the morning void, from the first morning void to the one of the next day.</description>
        <time_frame>Baseline (the last available assessment prior to the first dose of study medication), Day 7</time_frame>
        <population>Pharmacodynamic set Part A (PD-A): The PD set consisted of all randomized subjects who received at least one dose of randomized study medication for Part A, and who had a non missing baseline value and at least one post-baseline value for at least one pharmacodynamic variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Insulin</title>
            <description>Placebo administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5mg+ Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7 - Pharmacodynamic (PD) Set</title>
          <description>The 24-hour period is defined based on the morning void, from the first morning void to the one of the next day.</description>
          <population>Pharmacodynamic set Part A (PD-A): The PD set consisted of all randomized subjects who received at least one dose of randomized study medication for Part A, and who had a non missing baseline value and at least one post-baseline value for at least one pharmacodynamic variable.</population>
          <units>g/24-hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.16" spread="30.337" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="96.55" spread="30.083"/>
                    <measurement group_id="O3" value="101.28" spread="20.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</title>
        <description>Total daily insulin dose is defined as the sum of all insulin doses (basal+bolus+premixed) for each day. Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.</description>
        <time_frame>Baseline (the last available assessment on or prior to the first dose of study medication), Day 7</time_frame>
        <population>Pharmacodynamic set Part A (PD-A): The PD set consisted of all randomized subjects who received at least one dose of randomized study medication for Part A, and who had a non missing baseline value and at least one post-baseline value for at least one pharmacodynamic variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Insulin</title>
            <description>Placebo administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5mg+ Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</title>
          <description>Total daily insulin dose is defined as the sum of all insulin doses (basal+bolus+premixed) for each day. Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.</description>
          <population>Pharmacodynamic set Part A (PD-A): The PD set consisted of all randomized subjects who received at least one dose of randomized study medication for Part A, and who had a non missing baseline value and at least one post-baseline value for at least one pharmacodynamic variable.</population>
          <units>percent chagne</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.97" spread="5.280" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="-36.86" spread="3.324"/>
                    <measurement group_id="O3" value="-39.13" spread="2.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Basal Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</title>
        <description>Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.</description>
        <time_frame>Baseline (the last available assessment on or prior to the first dose of study medication), Day 7</time_frame>
        <population>Pharmacodynamic set Part A (PD-A): The PD set consisted of all randomized subjects who received at least one dose of randomized study medication for Part A, and who had a non missing baseline value and at least one post-baseline value for at least one pharmacodynamic variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Insulin</title>
            <description>Placebo administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5mg+ Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Basal Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</title>
          <description>Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.</description>
          <population>Pharmacodynamic set Part A (PD-A): The PD set consisted of all randomized subjects who received at least one dose of randomized study medication for Part A, and who had a non missing baseline value and at least one post-baseline value for at least one pharmacodynamic variable.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.75" spread="7.215" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="-36.74" spread="5.671"/>
                    <measurement group_id="O3" value="-39.63" spread="3.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Bolus Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</title>
        <description>Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.</description>
        <time_frame>Baseline (the last available assessment on or prior to the first dose of study medication), Day 7</time_frame>
        <population>Pharmacodynamic set Part A (PD-A): The PD set consisted of all randomized subjects who received at least one dose of randomized study medication for Part A, and who had a non missing baseline value and at least one post-baseline value for at least one pharmacodynamic variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Insulin</title>
            <description>Placebo administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5mg+ Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Bolus Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</title>
          <description>Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.</description>
          <population>Pharmacodynamic set Part A (PD-A): The PD set consisted of all randomized subjects who received at least one dose of randomized study medication for Part A, and who had a non missing baseline value and at least one post-baseline value for at least one pharmacodynamic variable.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.56" spread="5.905" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="-36.06" spread="4.238"/>
                    <measurement group_id="O3" value="-39.89" spread="3.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose (FPG) (mg/dL) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</title>
        <time_frame>Baseline (the last available assessment on or prior to the first dose of study medication), Day 7</time_frame>
        <population>Pharmacodynamic set Part A (PD-A): The PD set consisted of all randomized subjects who received at least one dose of randomized study medication for Part A, and who had a non missing baseline value and at least one post-baseline value for at least one pharmacodynamic variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Insulin</title>
            <description>Placebo administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5mg+ Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose (FPG) (mg/dL) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</title>
          <population>Pharmacodynamic set Part A (PD-A): The PD set consisted of all randomized subjects who received at least one dose of randomized study medication for Part A, and who had a non missing baseline value and at least one post-baseline value for at least one pharmacodynamic variable.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="41.31" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="-10.4" spread="62.10"/>
                    <measurement group_id="O3" value="-13.1" spread="44.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated Systolic Blood Pressure (mmHG) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</title>
        <time_frame>Baseline (the last available assessment on or prior to the first dose of study medication), Day 7</time_frame>
        <population>Pharmacodynamic set Part A (PD-A): The PD set consisted of all randomized subjects who received at least one dose of randomized study medication for Part A, and who had a non missing baseline value and at least one post-baseline value for at least one pharmacodynamic variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Insulin</title>
            <description>Placebo administered orally once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5mg+ Insulin</title>
            <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10mg + Insulin</title>
            <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Seated Systolic Blood Pressure (mmHG) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set</title>
          <population>Pharmacodynamic set Part A (PD-A): The PD set consisted of all randomized subjects who received at least one dose of randomized study medication for Part A, and who had a non missing baseline value and at least one post-baseline value for at least one pharmacodynamic variable.</population>
          <units>mmHG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="7.81" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="-2.1" spread="7.71"/>
                    <measurement group_id="O3" value="1.5" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious adverse event (AE): onset on or after the 1st day of dose up to on or prior to the last day of dose plus 4 days. Serious AE: onset on or after the 1st day of dose up to on or prior to the last day of dose plus 30 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo + Insulin</title>
          <description>Placebo administered orally once daily in the morning.</description>
        </group>
        <group group_id="E2">
          <title>Dapagliflozin 5mg + Insulin</title>
          <description>Dapagliflozin 5 mg administered orally once daily in the morning.</description>
        </group>
        <group group_id="E3">
          <title>Dapagliflozin 10 mg + Insulin</title>
          <description>Dapagliflozin 10 mg administered orally once daily in the morning.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version: 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>THIRST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>MUMPS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>URINE OUTPUT INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>POLLAKIURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yu Shimizuishi</name_or_title>
      <organization>AstraZeneca K.K.</organization>
      <phone>81 6 7711 4669</phone>
      <email>Yu.Shimizuishi@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

